Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07051187 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial to Evaluate the Efficacy and Safety of WGc0201 in Patients With Chronic Hepatitis B Virus Infection

Study acronym: WGc0201-HBV
StatusRecruiting
PhasePhase 1
SponsorJiyan Liu
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion pushed from Jul 30, 2026 to Sep 1, 2027
    • Start date: Apr 1, 2026 to Sep 1, 2026
    • Study completion pushed from Jul 30, 2027 to Sep 1, 2031
    v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 30, 2025 to Apr 1, 2026
    • Study sites: 0 to 1
    v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Jiyan Liu
3 trials monitored
See all monitored trials
Existing nucleoside analogues (NAs) and interferon therapy for chronic hepatitis B (CHB) have limitations, including drug resistance, low HBsAg clearance rates, and irreversible immunosuppression. Therapeutic vaccines, by activating virus-specific T cells and B cells, hold promise for achieving functional cure (HBsAg clearance + sustained HBV DNA negativity). This study is an open-label, single-arm, dose-escalation Phase I clinical trial. The study population consists of patients with chronic hepatitis B virus infection who have achieved virological stability following standard antiviral therapy. Phase I (dose exploration): three dose groups, with three patients per group. The primary objective is to observe and evaluate the safety of the WGc0201 vaccine in the study population (incidence and severity of adverse events).
Trial Details
NCT Number NCT07051187
Lead Sponsor Jiyan Liu
Collaborators: West China Hospital
Conditions
(from sponsor)		 Chronic Hepatitis B Virus (Hbv)
Related terms Hepatitis B, Hepatitis B, Chronic
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov